One biopsy may not show the whole immune picture in a glioblastoma
Original title: Regional reproducibility of immune expression programs in glioblastoma and implications for single-biopsy assessment
How far along is this research?
This is a preprint. Other scientists have not checked it yet, so treat it as an early signal rather than an answer.
This looked at stored tumor samples to guide testing, not a new treatment.
The short version
Immune signs can differ from one part of a brain tumor to another.
What was studied. Researchers took a second look at public data from 75 glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary biopsies. The samples came from 19 patients. They scored fourteen immune measures in each sample.
What they found. Most immune measures changed a lot across parts of the same tumor. A measure of CD8 immune cells varied the most. One measure, called interferon, stayed the most alike within each patient. Samples from two liver cancer groups were more alike than the brain tumor samples.
What this means, and what it doesn't
What it could mean: An immune test from one biopsy may not speak for the whole tumor. The authors say tissue should be tested from more than one spot. That could give a truer picture before immune treatment.
What it doesn't mean: This is not a new treatment, and it is not a cure. No one was given a drug here. The team reused data that was already collected. It does not change your care today. More work is needed before testing habits change.
Source: bioRxiv (preprint), October 9, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.